Legal & General Group
NPCE icon

Legal & General Group’s Neuropace NPCE Stock Holding History

Legal & General Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.8K Sell
2,190
-412
-16% -$6.18K ﹤0.01% 2845
2025
Q4 		$40.2K Sell
2,602
-77
-3% -$1.03K ﹤0.01% 2787
2025
Q3 		$27.6K Hold
2,679
– – ﹤0.01% 2917
2025
Q2 		$29.8K Buy
2,679
+1,239
+86% +$15.5K ﹤0.01% 2851
2025
Q1 		$17.7K Sell
1,440
-68
-5% -$851 ﹤0.01% 2983
2024
Q4 		$16.9K Hold
1,508
– – ﹤0.01% 3089
2024
Q3 		$10.5K Hold
1,508
– – ﹤0.01% 3262
2024
Q2 		$11.4K Buy
+1,508
New +$15.2K ﹤0.01% 3269
2022
Q2 		– Sell
-730
Closed -$6K – 3612
2022
Q1 		$6K Hold
730
– – ﹤0.01% 3490
2021
Q4 		$7K Hold
730
– – ﹤0.01% 3519
2021
Q3 		$12K Hold
730
– – ﹤0.01% 3417
2021
Q2 		$17K Buy
+730
New +$16.9K ﹤0.01% 3349

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Legal & General Group's NPCE Position: Q1 2026 in Review

Legal & General Group reduced its Neuropace (NPCE) stake by 16% in Q1 2026, selling an estimated $6.18K and leaving 2,190 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2845.

Legal & General Group first reported a position in NPCE in Q2 2021 and has held it in 12 quarters since. The position peaked at $40.2K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Legal & General Group held 2,190 shares of Neuropace worth $28.8K as of Q1 2026.
  • Legal & General Group sold 412 Neuropace shares in Q1 2026, an estimated $6.18K.
  • Neuropace made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2845 holding.
  • Legal & General Group first reported a position in Neuropace in Q2 2021 and has held it in 12 quarters since.
  • Legal & General Group's Neuropace position peaked at $40.2K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.